# Maurice Ferre, M.D.

> Maurice Ferre, M.D. is a Series A investor at InSightec (Miami) backing Medical Device and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [InSightec](https://shizune.co/investors/profile/insightec)
- Location: Miami, United States
- Total investments: 6
- Last investment: Jun 2022
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/maurice-r-ferre-m-d-9611b36
- Website: https://www.lumiraventures.com/team-member/maurice-r-ferre-md

Maurice Ferre, M.D. is a Series A investor at InSightec in Miami focused on Medical Device and Medical. Dr. Maurice R. Ferré was the founding President and Chief Executive Officer of MAKO Surgical Corp, serving from 2004 until the acquisition of the company by Stryker Corp. for $1.7 billion in 2014.In June 2007, Dr. Ferré received the Ernst & Young Entrepreneur of the Year 2007 award for emerging companies in Florida. In 1993, he foundedVisualization Technology, Inc., a medical device company for image-guided surgery, where he served as Chief Executive Officer until 2002 when the company was acquired by GE Healthcare, the healthcare division of the General Electric Company. Dr. Ferré served as Vice President of Strategic Development for GE Navigation, a Division of GE Healthcare, until 2004.Dr. Ferré holds an M.D. and a Master’s degree in Public Health from Boston University.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $10M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 3 | 50% |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Big Data | 1 | 17% |
| Hardware | 1 | 17% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Seed | 1 | 17% |
| Angel | 1 | 17% |
| Series B | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| United Kingdom | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DermaSensor | DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $10M | Series B | Jun 15, 2022 |  |
| DermaSensor | DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $10M | Series A | Jun 15, 2022 |  |
| TympaHealth | TympaHealth has developed the world's first ear and hearing health assessment system. The Tympa system empowers non-specialists to perform high definition digital otoscopy, microsuction wax removal and a hearing screening, all in a single 30 minute appointment. Users can also upload patient images and video to the secure cloud, where they canbe reviewed by ENT specialists anywhere in the world. | $8M | Seed | Feb 17, 2022 |  |
| Heru | Heru Inc. (www.SeeHeru.com) has developed patented autonomous AI-powered vision diagnostics and augmentation software for use on commercially available AR/VR devices. This technology exceeds traditional standards of care in clinical equivalence, usability, cost, size, and portability. Heru is the only cross-platform solution that canautonomously diagnose vision defects and customize individual vision augmentation based on the user’s unique vision defects. Heru originated as a spinout from Bascom Palmer Eye Institute. In December 2020, Heru announced FDA registration and a seed round led by Fred Drasner, Maurice R. Ferre, M.D., Fred H. Moll, M.D., and a consortium of investors with extensive experience developing, launching, and scaling cutting-edge medical technologies. | $30M | Series A | May 20, 2021 |  |
| DermaSensor | DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions forpotential cancer in seconds. | $11.5M | Series A | Jun 04, 2020 |  |
| Naya Health | Naya Health reinvents nutrition for both babies and families with ingenious products and game-changing insights.Naya Health Co., is a seed stage company developing digital, consumer-focused health products that will revolutionize the well-being and lifestyle of mothers and babies. The company's initial product is a first-of- kind, radicallyimproved breast pump for nursing moms. Naya Health helps modern mothers reach their breastfeeding goals by offering products that integrate into a mom’s busy life. | $700K | Angel | Nov 27, 2014 |  |

6 of 6 investments shown.

## Co-investors
- [Ceros Capital Markets](https://shizune.co/investors/profile/ceros-capital-markets) — VC Fund, 2 deals together
- [D1 Capital Partners](https://shizune.co/investors/profile/d1-capital-partners) — VC Fund, 2 deals together
- [Astia Angels](https://shizune.co/investors/profile/astia-angels) — VC Fund, 1 deal together
- [Hedgewood](https://shizune.co/investors/profile/hedgewood) — VC Fund, 1 deal together
- [KHP MedTech Innovations](https://shizune.co/investors/profile/khp-medtech-innovations) — VC Fund, 1 deal together
- [Krillion Ventures](https://shizune.co/investors/profile/krillion-ventures) — VC Fund, 1 deal together

## About InSightec

VC Fund · Tirat Carmel, Israel

InSightec is the pioneer and global leader in MR guided focused ultrasound technology for image guided acoustic surgery.ExAblate® 2000 system was the first system to use the MR guided focused ultrasound technology. The ExAblate system received CE mark in 2002 and the Food and Drug Administration (FDA) approval in 2004 for the treatment ofsymptomatic uterine fibroids. ExAblate received the European CE Mark for pain palliation of bone metastases in June 2007 and for adenomyosis in June 2010. This device has won numerous innovation awards and has been used to treat thousands of patients around the world.

5 contacts available at InSightec.

| Name | Title | Profile |
| --- | --- | --- |
| Maurice Ferre, M.D. | CEO & Chairman | https://shizune.co/investors/profile/maurice-ferre |
| Alexandru Popescu | Commercial Leader EEMEA& RCA | https://shizune.co/investors/profile/alexandru-popescu |
| Chris Marrus | CCO | https://shizune.co/investors/profile/chris-marrus-789b |
| Ivan Delevic | SVP Strategic Marketing and Business Development | https://shizune.co/investors/profile/ivan-delevic |
| Jack Campo | Chief Legal Officer | https://shizune.co/investors/profile/jack-campo-c922 |

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Medical Device Angel Investors](https://shizune.co/investors/medical-device-angel-investors)
- [Medical Device Angel Investors in United States](https://shizune.co/investors/medical-device-angel-investors-united-states)
- [Medical Device Angel Investors in United Kingdom](https://shizune.co/investors/medical-device-angel-investors-united-kingdom)
- [Medical Angel Investors in United Kingdom](https://shizune.co/investors/medical-angel-investors-united-kingdom)

## FAQ

### What does Maurice Ferre, M.D. invest in?

Maurice Ferre, M.D. invests primarily in Medical Device, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Maurice Ferre, M.D.'s check size?

Maurice Ferre, M.D. typically joins rounds of $10M–$30M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Maurice Ferre, M.D. participates in.

### When did Maurice Ferre, M.D. last invest?

The most recent investment recorded for Maurice Ferre, M.D. closed in Jun 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co